



## Role of Alphafeto Protein, Beta Human Chorionic Gonadotropin and Unconjugated Estriol as Predictor of Preeclampsia.

<sup>1\*</sup>Vandana Yadav, <sup>2</sup>A K Verma, <sup>3</sup>Nagraj Soni, <sup>4</sup>G G Kaushik & <sup>5</sup>J S Broca

(<sup>1</sup>Ph.D. Scholar, <sup>2</sup>Sr Professor & Head), Department of Biochemistry, RNT Medical College, Udaipur, Rajasthan, India.

<sup>3</sup>Sr. Demonstrator, <sup>4</sup>Sr. Professor & HOD, Department of Biochemistry, J.L.N. Medical College, Ajmer, Rajasthan, India.

<sup>5</sup>Sr. Professor of Community Medicine, JLN Medical College, Ajmer, Rajasthan, India.

**Corresponding Author: Vandana Yadav**

### ABSTRACT:

**Background:** Pre-eclampsia remains a major cause of prenatal morbidity and mortality worldwide. Cause of pre-eclampsia is still ill defined and there is no appropriate test for predicting occurrence of the disorder. This study aimed to assess association between pre-eclampsia and serum levels of alphafeto protein (AFP),  $\beta$ -human chorionic gonadotropin ( $\beta$ -hCG), and unconjugated estriol (uE<sub>3</sub> or free estriol). **Method:** The study carried out on 500 pregnant women admitted to R.N.T. Medical college, Udaipur. Subjects were divided into 3 groups normotensive pregnancies, mild preeclampsia and severe preeclampsia. The level of  $\beta$ -hCG, AFP and unconjugated estriol were measured using Enzyme-linked Immunosorbent Assay (ELISA) method and results were analyzed statistically using SPSS software. **Results:** The Mean  $\pm$  SD levels of serum urea, creatinine, uric acid, AFP and  $\beta$ -HCG were found to be significantly increased and unconjugated estriol was found significantly decreased in mild & severe (P<0.001) pre-eclamptic women, as compared to normotensive controls. **Conclusion :** The population-specific median values for the three biomarkers (AFP,  $\beta$ -HCG, uE<sub>3</sub>) may

be used as reference values during prenatal screening in pregnant women.

**Keywords:** AFP,  $\beta$ -HCG, uE<sub>3</sub>, pre-eclampsia

**INTRODUCTION:** Pre-eclampsia is a multisystem disorder of unknown etiology with hypertension, proteinuria and/or edema which predisposes to potentially lethal complications such as eclampsia, abruption-placentae, acute renal failure, cerebral hemorrhage and circulatory collapse. Approximately 7 to 10% of all pregnancies are complicated by hypertensive disease, 70% of which are gestational hypertension – pre-eclampsia related and 30% are due to chronic hypertension (Sibai, 2010). Pre-eclampsia is defined as a systolic blood pressure  $\geq$  140 mm Hg or diastolic blood pressure  $\geq$  90 mm Hg on 2 occasions at least 4 hrs apart after 20 weeks gestation in women with a previously normal blood pressure or  $\geq$  160 mm Hg systolic or  $\geq$  110 mm Hg diastolic, confirmed within a short interval (minutes) to facilitate timely antihypertensive therapy and proteinuria  $\geq$  300 mg / 24 hrs or a protein / creatinine ratio  $\geq$  0.3 mg / dl or a dipstick reading of  $\geq$  1+. In the absence of proteinuria, pre-eclampsia is diagnosed as new-onset hypertension with the new onset of any the following



: thrombocytopenia, renal insufficiency, or cerebral or visual systems. (ACOG, 2013) Alfa – fetoprotein is a glycoprotein produced by the fetal liver and gastrointestinal tract. Its level is raised due to functional alteration of trophoblastic cells, leading to increased leakage, as trophoblastic dysfunction is the primary problem in pre-eclampsia (Dayal M, 2011). It has been suggested that maternal serum alpha – fetoprotein (MSAFP) screening, apart from identifying fetuses with open neural tube defects and chromosomal abnormalities, could also identify pregnancies at high risk of adverse outcomes (seppala M, 1973). The human chorionic gonadotropin (hCG) is a glycoprotein composed of two non – covalently linked subunits,  $\alpha$  and  $\beta$ , and is produced by syncytiotrophoblast cells of the placenta. Maternal serum hCG peaks at 8 – 10 wk of gestation and then declines to reach a plateau at 18 – 20 wk of gestation. The free  $\beta$  - subunit can derive from three sources, namely, direct trophoblast cell production, dissociation of hCG into free  $\alpha$  and free  $\beta$  – subunits, and by macrophage or neutrophil enzymes nicking the hCG molecule (cole LA et al 1993). The free  $\beta$  – hCG circulating in maternal serum corresponds to only about 0.3 – 4% of the total hCG (spencer K 1991). The normal placenta differentiates during pregnancy with the cytotrophoblast dominant in early gestation and the syncytiotrophoblast dominant in late pregnancy. Placental vascular damage leading to decreased oxygen supply might result in increased hCG production by hyperplastic cytotrophoblastic cells (Majumdar S et al 2005). Although the placenta is the

source of estriol, this hormone may reflect fetal steroid genesis. The fetal adrenal glands produce dehydroepiandrosterone sulfate (DHEA-S), which is hydroxylated by the fetal liver into 16—hydroxy-DHEA-S. The latter is transported to the placenta where it undergoes desulfation by steroid sulfatase and is finally aromatized to estriol (Newby D et al 2000). In the early phase of pregnancy, fetal adrenal DHEA-S production is independent of fetal ACTH, but in the second trimester ACTH is required for adrenal function. Henceforth, 90% of the estriol production originates from DHEA-S synthesized by the fetal adrenal glands. In fact, unlike total estriol, unconjugated estriol is produced almost entirely by the fetal-placental unit and therefore is a more sensitive indicator of fetal health. The aim of this present study was to find out the role of AFP ,  $\beta$  – hCG and unconjugated estriol in pathogenesis of pre-eclampsia and its association with severity of pre-eclampsia.

**MATERIAL AND METHODS:** The present study was conducted at the Department of obstetrics and gynecology, R.N.T. Medical College, Udaipur, after taking approval from ethical committee . The prospective randomized study was conducted on 500 pregnant women of gestational age between 12-24 weeks with singleton pregnancy. Patients with chronic hypertension, twin pregnancy, molar pregnancy, chromosomally abnormal fetus, diabetes, chronic renal diseases, autoimmune

disorders, thrombophelias, family history of diabetes mellitus, cardiovascular diseases were excluded from the study. Apart from routine hematological investigations, estimation of AFP,  $\beta$ -hCG and unconjugated estriol levels in maternal serum were done by ELISA technique. Blood samples were collected with all aseptic precautions. Preeclampsia was considered as defined by American college of Obstetrics and Gynecologists (ACOG, 2013) the systolic blood pressure  $\geq 140$  mm Hg or  $\geq 90$  mm Hg diastolic on two occasions at least 4 hrs apart after 20

wks gestation in women with a previously normal blood pressure. Severe preeclampsia is defined by the systolic blood pressure  $\geq 160$  mm Hg or diastolic  $\geq 110$  mm Hg on 2 occasions 4 hours or more apart while the patient is bed rest. Statistical analyses were performed with SPSS software. The differences of pregnancy outcomes among the control, mild pre-eclampsia, and severe pre-eclampsia groups were carried out with ANOVA, student's t-test. \* p-value  $<0.05$  is significant.

**RESULTS:**

**Table 1:** Demographic characteristics of normal pregnancy and pre-eclampsia cases :

Sr. No.	Parameters	Normal Pregnancy (n=250)	Mild Pre-eclampsia (n=200)	Severe Pre-eclampsia (n=50)	P- Value
1.	Means gestational age (weeks)	20.2 $\pm$ 2.25	22.42 $\pm$ 3.25	21.3 $\pm$ 2.9	p> 0.05
2.	Mean maternal age (years)	20.58 $\pm$ 2.3	23.2 $\pm$ 3.1	21.8 $\pm$ 2.9	p> 0.050
3.	Mean systolic blood pressure (mm Hg)	114.25 $\pm$ 7.42	156.24 $\pm$ 7.90	183.86 $\pm$ 8.24	p< 0.001
4.	Mean diastolic blood pressure (mm Hg)	76.61 $\pm$ 8.67	99.51 $\pm$ 4.87	113.06 $\pm$ 5.11	p< 0.001

**Table 2:** Laboratory data of normal pregnancy, Mild and severe pre-eclampsia :

Sr. No.	Parameters	Normal Pregnancy (n=250)	Mild Pre-eclampsia (n=200)	Severe Pre-eclampsia (n=50)	P- Value
1.	Urea (mg/dl)	15.50 $\pm$ 2.59	24.52 $\pm$ 3.99	35.46 $\pm$ 4.94	p< 0.001
2.	Creatinine (mg/dl)	0.74 $\pm$ 0.14	0.83 $\pm$ 0.07	1.46 $\pm$ 0.27	p< 0.001
3.	Uric acid (mg/dl)	4.85 $\pm$ 1.31	5.83 $\pm$ 1.00	7.60 $\pm$ 0.77	p< 0.001
4.	AFP (ng / ml)	52.50 $\pm$ 15.52	116.41 $\pm$ 7.92	151.04 $\pm$ 7.2	p< 0.001
5.	Beta HCG (mIU / ml)	8091.44 $\pm$ 1493.68	15850.26 $\pm$ 789.53	19791.70 $\pm$ 987.02	p< 0.001
6.	uE <sub>3</sub> (ng / ml)	10.78 $\pm$ 1.43	7.02 $\pm$ 1.87	5.42 $\pm$ 1.81	p< 0.001

Mild pre-eclampsia cases of those who showed  $\geq 140$ mmHg systolic or  $\geq 90$ mmHg diastolic on 2 occasions at least 4 hrs apart after 20wks gestation in women with a previously normal blood pressure. Severe pre-eclampsia cases of those who showed  $\geq 160$  mmHg systolic or  $\geq 110$ mmHg diastolic, on 2 occasions 4 hours or more apart while the patient is at bed rest (ACOG, 2013). Out of 250 pre-eclampsia patients, 200 were mild pre-eclampsia and 50 were severe pre-eclampsia. Table:1 illustrates the Mean  $\pm$  SD levels of Systolic and diastolic blood pressure were significantly increased in mild and severe ( $P < 0.001$ ) pre-eclampsia women, when compared with normotensive. Table-2 shows, the Mean  $\pm$  SD levels of serum urea, creatinine, uric acid, AFP and  $\beta$ -HCG were found to be significantly increased and unconjugated estriol was found significantly decreased in mild & severe ( $P < 0.001$ ) pre-eclamptic women, as compared to normotensive controls.

**DISCUSSION :** In preeclampsia the rise of blood pressure is due to vasoconstriction and impaired angiogenesis leading to hypoxia and hyperplasia of trophoblastic cells which causes hypersecretion of placental hormone ultimately leading to high level of circulating  $\beta$ -hCG. In this study, we found that serum  $\beta$ -hCG levels were significantly elevated in severe preeclampsia, compared with the controls. This finding indicates that an abnormal secretory function exists in patients with severe preeclampsia. In preeclampsia, placental pathologic

examination reveals focal cellular necrosis in the syncytiotrophoblast and increased mitotic activity with cellular proliferation in the cytotrophoblast (Jones CJP 1980). In addition, the proliferating cytotrophoblast in severe pre-eclampsia is rapidly transformed into syncytiotrophoblast within 72 hours (Hoshina, 1982). The normal placenta differentiates during pregnancy with the cytotrophoblast dominant in late pregnancy (Enders AC 1965). It is well known that the cytotrophoblast is an undifferentiated stem cell and the syncytiotrophoblast is a differentiated trophoblast transformed from the cytotrophoblast (Kliman HJ, 1987). In 1934, Smith et al talked about increasing hCG levels in severe preeclampsia for the first time. Luckas M (1998), Benn PA (1996) & Ashour AM (1997) indicate that an unexplained elevation of serum hCG significantly correlated with the occurrence of preeclampsia. By contract Pouta et al and Aguilina et al demonstrated no relation between levels of serum hCG and severity of pre-eclampsia. Stamilio et al also found no association between severe preeclampsia and elevated second trimester hCG levels. Alpha-feto protein (AFP) is produced in the fetal liver and yolk sac, and secreted into the fetal circulation and amniotic fluid, passed into the maternal circulation via the placenta and its concentration is 100 fold increase in the first trimester of pregnancy compared with non-pregnant women. In our study, unexplained high levels of MSAFP have been associated with pre-eclampsia. Our findings are consistent with the study by Tikkanen et al (2007),



Waller et al (1996) and Willaims et al (1992) about the correlation of pre – eclampsia and MSAFP, while Khoo's study (1978) showed, in preeclampsia women; significantly lower mean AFP values were obtained. Raly et al also found the AFP values in the severe pre – eclampsia group differed significantly from all other groups. Brazeros et al (1999) reported that the explanation for the association between elevated maternal serum alphafeto protein and adverse pregnancy outcome is not clear, but is probably a marker of placental dysfunction, including partial placental abruption, fetomaternal bleeding and abnormal implantation. Although the placenta is the source of estriol, this hormone may reflect fetal steroidogenesis. The fetal adrenal glands produce dehydroepiandrosterone sulfate [DHEA-S], which is hydroxylated by the fetal liver into 16—hydroxy-DHEA-S. The latter is transported to the placenta where it undergoes desulfation by steroid sulfatase and is finally aromatized to estriol. In the early phase of pregnancy, fetal adrenal DHEA-S production is independent of fetal ACTH, but in the second trimester ACTH is required for adrenal function. Henceforth, 90% of the estriol production originates from DHEA-S synthesized by the fetal adrenal glands. In fact, unlike total estriol, unconjugated estriol is produced almost entirely by the fetal placental unit and therefore is a more sensitive indicator of fetal health. Unconjugated estriol is a variable independent of maternal age and therefore it can be used alone or in combination with maternal age for the determination of the relative risk of Down's syndrome

or Edward's syndrome. In a routine screening programme, maternal serum unconjugated estriol has poor predictive power if used as a single marker, but its inclusion contributes to improving the predictive value of age and alpha fetoprotein.

**CONCLUSION:** The new markers (AFP,  $\beta$ -hCG, uE3) provide an opportunity to study the early natural history of disease and possibly to conduct treatment trials. The present study confirmed the elevated levels of AFP,  $\beta$ -hCG and low level of unconjugated estriol are associated with pre-eclampsia.

#### REFERENCES:

1. Ashour AM, Lieberman ES, Haug LE, Repke JT. The value of elevated second – trimester beta-human chorionic gonadotropin in predicting development of pre – eclampsia. *Am J Obstet Gynecol* 1997;176(2): 438-42.
2. Aquilina J, Maplethorpe R, Ellis P, Harrington K. Correlation between second trimester maternal serum inhibin – A and human chorionic gonadotrophin for the prediction of pre – eclampsia. *Placenta* 2000;21(5-6): 487-92.
3. Benn PA, Horne D, Briganti S, Rodis JF, Clive JM. Elevated second – trimester maternal serum hCG alone or in combination with elevated alpha – fetoprotein. *Obstet Gynecol* 1996;87(2): 217-22.
4. Braseros WF, Groves, Donnfield AE. Unexplained elevated maternal serum alpha – fetoprotein levels and perinatal outcome in an urban clinic population. *Am. J. obstet. Gynecol.* 171(1); 1030-35, 1994.
5. Bernstein IM, Barth RA, Miller R, Capeless EL. Elevated maternal serum alpha – fetoprotein: association with placental sonolucencies, fetoprotein

- hemorrhage, vaginal bleeding, and pregnancy outcome in the absence of fetal anomalies. *Obstet Gynecol* 1992;79(1):71-4.
6. Enders AC. Formation of syncytion from cytotrophoblast in the human placenta. *Obstet Gynecol* 25(2): 378-86, 1965.
  7. Hosina M, Boothby M, Boime I: Cytological localization of chorionic gonadotropin and placental lactogen mRNAs during development of the human placenta. *J. Cell Biol* 93(1): 190-98; 1982.
  8. Jones CJP, Fox H. An ultrastructural and ultrahistochemical study of the human placenta in maternal pre – eclampsia. *Placenta*. 1 : 61-66. 1980.
  9. Kilman HJ, Feimann MA, Strauss JF. Differentiation of human cytotrophoblast into syncytotrophoblast in culture. *Trophoblast Res.* 2(3): 407-21, 1987.
  10. Kuo PL, Lin CC, Lin YH, Guo HR. Placental sonolucency and pregnancy outcome in women with elevated second trimester serum alpha – fetoprotein levels. *J Formos Med Assoc* 2003;102(5): 319-25.
  11. Khoo SK, Chang A, Mackay EV. A Comparison of maternal serum levels of alpha–fetoprotein in normal and pre–eclampsia pregnancies. *Br J Obstet Gynaecol* 1978;85(12): 914-20.
  12. Lukas M, Hawe J, Meekins j, Neilson J, Walkinshaw S. Second trimester serum free beta human chorionic gonadotrophin levels as a predictor of pre–eclampsia. *Acta Obstet Gynecol Scand* 1998;77(4): 381-4.
  13. Mizejewski GJ. Biological roles of alpha–fetoprotein during pregnancy and perinatal development, *exp Bio; Med* (Maywood) 2004;229(6):439-63.
  14. Neggers YH, Goldenberg RL, DuBard MB, Cliver SP. Increased risk of preterm delivery with elevated maternal alpha – fetoprotein and plasma zinc levels in African – American women. *Acta Obstet Gynecol Scand* 2000;79(3):160-4.
  15. Puota AM, Hartikainen AL, Vouteenaho OJ, Ruokonen AO, Laatikainen TJ. Midtrimester N – terminal proatrial natriuretic peptide, free beta hCG and alpha – fetoprotein in predicting pre – eclampsia *Obstet Gynecol* 1998;91(6): 940-4.
  16. Raty R, Koskinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U. Prediction of pre – eclampsia with maternal mid – trimester total renin, inhibin A, AFP and free beta – hCG levels. *Prenat daign* 1999;19(2): 122-7.
  17. Smith GC, Smith ow. Excessive gonadostimulatory hormone and subnormal amounts of oestin I toxemia of late pregnancy. *Am J obstet Gynecol* 107:128-45, 1934.
  18. Spencer K. Evaluation of an assay of the free beta – subunit of choriogonadotropin and its potential value in screening for Down’s syndrome *clin chem.* 1991; 37(6): 809-814.
  19. Tikkanen M, Hamalainen E, Nuutila M, Paavonen J, Ylikorkala O, Hiilesmaa V. Elevated maternal second – trimester serum alpha – fetoprotein as a risk factor for placental abruption. *Prenat Diagn* 2007;27(3):240-3.
  20. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha – fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. *Obstet Gynecol* 1996;88(5): 816-22.
  21. Williams MA, Hickok DE, Zinegheim RW, Luthy DA, Kimelman J, Nyberg DA, et al. Elevated maternal serum alpha – fetoprotein levels and midtrimester placental abnormalities in relation subsequent adverse pregnancy outcomes. *Am J Obstet Gynecol* 1992;167( Pt 1): 1032-7.
  22. Wald NJ, Morris JK, Ibison J, Wu T, George LM. Screening in early pregnancy for pre – eclampsia using Down syndrome quadruple test

- markers. *Prenat Diagn* 2006;26(6): 559-64.
23. Sibal B.M. (2010 b). Pre – eclampsia. In J.T. Queenan, J. Hobbins & C.Y. spong (Eds.). *protocols for High – Risk pregnancies* (5<sup>th</sup> ed.). West Sussex, UK: Willey. Blackwell.
  24. The American college of obstetricians and Gynecologists. Hypertension in pregnancy Report of the American college of obstetricians and Gynecologists. *A COG* 2013; 122(5), 1122-31.
  25. Dayal M, Gupta P, Verma M, Ghosh UK, Bhargava A. Role second trimester maternal serum markers as predictor of pre – eclampsia. *J. Obstet. Gynecol. India*. 2011 pag 38-41.
  26. Cole LA, kardana A, Park S4, Braunstein GD. The deactivation of hCG nicking and dissociation. *J. Clin. Endo. Meta* 1993; 76(3): 704-710.
  27. Spencer K. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome *clin. Chem*. 1991 ; 37(6): 809-814.
  28. Majumdar S, Dasgupta H, Bhattacharya K, Bhattacharya A. A study of placenta in normal and hypertensive pregnancies. *J. Ant. Soc. India* 2005; 54(2): 1-9.
  29. Newby D, Aitken DA, Howaston AG, Connor JM, 2000. placental synthesis of estriol in down's syndrome pregnancy. *Placenta* 21: 263-67.